Again Please: BioMarin Seeks Speedy EU Review For Hemophilia Gene Therapy
US BLA Submission For Roctavian Expected Next Year
BioMarin is planning to resubmit its EU marketing application for Roctavian soon and, as with the previously pulled application, it wants the regulators to fast-track the new filing.
